David Heusinkveld, MD
Internal Medicine · Nashville, TNNPI 1962499582
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 1,398 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,398 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Pfizer$2K
- Lilly USA, LLC$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Amgen$1K
- plus $12K from 54 others
What the payments were for
- Food & beverage$23,674100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,696 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 318 | $402,360 |
| EliquisApixaban | 201 | $164,208 |
| JardianceEmpagliflozin | 142 | $157,852 |
| XareltoRivaroxaban | 136 | $110,800 |
| MounjaroTirzepatide | 70 | $84,712 |
| JanuviaSitagliptin Phosphate | 95 | $77,513 |
| FarxigaDapagliflozin Propanediol | 77 | $71,272 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $66,690 |
| RybelsusSemaglutide | 34 | $55,830 |
| GemtesaVibegron | 51 | $41,157 |
| LinzessLinaclotide | 37 | $33,728 |
| RexultiBrexpiprazole | 16 | $28,168 |
| Invega SustennaPaliperidone Palmitate | 11 | $27,271 |
| VascepaIcosapent Ethyl | 31 | $26,946 |
| MyrbetriqMirabegron | 39 | $23,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $4,447 | $458,190352 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $1,718 | $195,109247 claims |
| Boehringer IngelheimJardiance, Tradjenta | $699 | $175,411165 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $485 | $138,071147 claims |
| MerckJanuvia, Janumet Xr | $656 | $96,165106 claims |
| Lilly USA, LLCMounjaro | $1,578 | $84,71270 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $739 | $78,66889 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $281 | $41,15751 claims |
| AbbVieLinzess, Namzaric | $1,427 | $40,05748 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $849 | $33,59658 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $679 | $28,16816 claims |
| Astellas Pharma US IncMyrbetriq | $294 | $23,03539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Nashville
- John AndersonNashville$1.5M
- Temidayo AbeNashville$113K
- Wayne RileyNashville$86K
- Leah CordovezNashville$64K
- Asad Al AboudNashville$44K
- Mark KouryNashville$41K
- Charlotte LohreyNashville$19K
- Malek Al-OmaryNashville$18K
- James GekasNashville$17K
- William LizarragaNashville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.